The phase 3 pediatric anticoagulant era

Neil A. Goldenberg, Brian R. Branchford

Research output: Contribution to journalReview articlepeer-review


In this issue of Blood, Brandão et al report the findings of an open-label, single-arm, phase 3 trial of the direct oral thrombin inhibitor dabigatran for extended secondary thromboprophylaxis in children with a history of venous thromboembolism (VTE)

Original languageEnglish (US)
Pages (from-to)459-460
Number of pages2
Issue number7
StatePublished - Feb 13 2020

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'The phase 3 pediatric anticoagulant era'. Together they form a unique fingerprint.

Cite this